



December 16th, 2021  
Luxna Biotech Co., Ltd.

## **Notice of Fundraising**

Luxna Biotech Co., Ltd. (President & CEO: Hideaki Sato, Headquarters: Suita-shi, Osaka, Japan), which develops highly effective and safe nucleic acid drugs by making full use of new artificial nucleic acids, is pleased to announce that it has raised approximately 1.22 billion yen through third-party allocation. In addition to shares from existing investors OUVVC I Investment Limited Partnership operated by Osaka University Venture Capital Co., Ltd., and Mizuho Life Science I Investment Limited Partnership operated by Mizuho Capital Co., Ltd., but also new shares to New Life Science I Investment Limited Partnership operated by Shinsei Capital Partners Co., Ltd., Handai Venture NVCC I Investment Limited Partnership operated by Nippon Venture Capital Co., Ltd., Healthcare Innovation Investment Limited Partnership operated by Healthcare Innovation Co., Ltd., and Ube Industries, Ltd.

The total amount of funds raised, including this time, will be approximately 2.3 billion yen, including a total of 330 million yen in capital subordinated loans from Japan Finance Corporation.

### ■ Background and purpose of financing

Since its establishment in December 2017 (business start: February 2018), our company is expected to be able to achieve both high activity and low toxicity, which was invented by a group of Professor Satoshi Obika of the Graduate School of Pharmaceutical Sciences, Osaka University. Based on the novel bridged artificial nucleic acid technologies (XNAs technologies), we carry out nucleic acid drug discovery and basic technology development for unmet medical needs by antisense oligonucleotides, in close collaboration with pharmaceutical companies, chemical companies, and universities. In October 2021, the development of an antisense oligonucleotide drug against hepatitis B virus by Aligos Therapeutics, the technology out-licensing company, which is the most advanced project, started in healthy subjects in the phase one clinical trial.

In order to further accelerate this situation and realize the clinical entry of the advanced jointly developed product while producing development candidate products, we have reached the Series B funding this time. Going forward, we will aim for further business development and overseas expansion while utilizing the extensive technology and knowledge of our shareholders in the nucleic acid pharmaceutical business and their global network. Through these, we will stage up joint drug discovery with pharmaceutical companies, promote the development of technology out-licensing destinations and search for out-licensing destinations, and accelerate in-house therapeutic programs treatment for subacute spinal cord injury and small cell lung cancer / treatment-resistant prostate cancer.



#### About Luxna Biotech Co., Ltd.

Luxna is a biotech to be founded to support patients who are suffering from diseases and to create oligonucleotide therapeutics by installing the nucleic acid pharmaceutical element technologies accumulated in Osaka University that promote safer and more effective oligonucleotide therapeutics in the clinical setting. Luxna actively promotes co-development with some pharmaceutical companies and in-house drug discovery with ASOs as our main development drugs.

In October 2021, it was certified as one of J-Startup KANSAI by the Kinki Bureau of Economy, Trade and Industry of the Ministry of Economy, Trade and Industry. For more information, please visit our website (<https://luxnabiotech.co.jp/>).

#### About Luxna XNAs technology

Luxna XNAs technology collectively means an innovative nucleic acid group of AmNA, scpBNA, GuNA and 5'-CP accumulated in Professor Obika's laboratory (Osaka University Graduate School of Pharmaceutical Sciences, Bioorganic Chemistry). Luxna XNAs technology could make available ASOs that satisfy requirements for both a high level of activity and low toxicity, and to take advantage of its characteristics of high affinity for mRNA and reduced hepatotoxicity.

#### **Luxna Biotech Co., Ltd.**

Headquarters and Research Institute: 2-8 Yamadaoka, Suita City, Osaka

Representative: Hideaki Sato

Founded: December 2017

Website: <https://luxnabiotech.co.jp/en/>

#### **Contact Info**

Luxna Biotech Co., Ltd. Administration Department

E-mail [info@luxnabiotech.co.jp](mailto:info@luxnabiotech.co.jp):

EOD